The treatment plan of the British Columbia Cancer Agency (BCCA) for DLBCL patients is that the patients receive three cycles of R-CHOP treatment achieving a complete remission (CR) by PET and then receive an additional cycle of R-CHOP treatment. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.